The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
Abstract
Purpose: To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed. Patients and Methods: Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases. All patients received chemotherapy according to COSS protocols. Thirty-eight patients underwent limb-sparing surgery, 12 patients underwent hemipelvectomy, and 17 patients did not undergo definitive surgery. Eleven patients received irradiation to the primary tumor site: four postoperatively and seven as the only form of local therapy. Results: Local failure occurred in 47 of all 67 patients (70%) and in 31 of 50 patients (62%) who underwent definitive surgery. Five-year overall survival (OS) and progression-free survival rates were 27% and 19%, respectively. Large tumor size (P = .0137), primary metastases (P = .0001), and no or intralesional surgery (P < .0001) were poor prognostic factors. In 30 patients with no or intralesional surgery, 11 patients with radiotherapy had better OS than 19 patients without radiotherapy (P = .0033). Among the variables, primary metastasis, large tumor, no or intralesional surgery, no radiotherapy, existence of primary metastasis (relative risk [RR] = 3.456; P = .0009), surgical margin (intralesional or no surgical excision; RR = 5.619; P < .0001), and no radiotherapy (RR = 4.196; P = .0059) were independent poor prognostic factors. Conclusion: An operative approach with wide or marginal margins improves local control and OS. If the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A System for the Surgical Staging of Musculoskeletal Sarcoma
ENNEKING, W. F., SPANIER, S. S., & GOODMAN, M. A. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198011000-00013 · Cited by 2,500
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Self-citationPrimary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s · Cited by 592
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Self-citationNeoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Self-citationClark, J. L., Unni, K. K., Dahlin, D. C., & Devine, K. D. (1983) · Cancer · Cited by 304
Tumor size and prognosis in aggressively treated osteosarcoma.
Bieling, P., Rehan, N., Winkler, P., Helmke, K., Maas, R., Fuchs, N., Bielack, S., Heise, U., Jurgens, H., Treuner, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.848 · Cited by 275
Self-citationPrimary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy
Rosen, G., Marcove, R. C., Huvos, A. G., Caparros, B. I., Lane, J. M., Nirenberg, A., Cacavio, A., & Groshen, S. (1983) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00625054 · Cited by 228
Anderson, P. M., Wiseman, G. A., Dispenzieri, A. A., Arndt, C. A. S., Hartmann, L. C., Smithson, W. A., Mullan, B. P., & Bruland, Ø. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.189 · Cited by 214
Interval between symptom onset and diagnosis of pediatric solid tumors
Pollock, B. H., Krischer, J. P., & Vietti, T. J. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80287-2 · Cited by 176
Cited by
Osteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Ritter, J., & Bielack, S. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq276 · Cited by 1,045
Self-citationBiology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Self-citationFertility preservation in female patients
Sonmezer, M. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh021 · Cited by 496
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 395
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Radiotherapy for local control of osteosarcoma
DeLaney, T. F., Park, L., Goldberg, S. I., Hug, E. B., Liebsch, N. J., Munzenrider, J. E., & Suit, H. D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.051 · Cited by 306
Duchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 305
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 298
Therapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Osteosarcoma: Review of the Past, Impact on the Future. The American Experience
Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_12 · Cited by 252
Proton‐based radiotherapy for unresectable or incompletely resected osteosarcoma
Ciernik, I. F., Niemierko, A., Harmon, D. C., Kobayashi, W., Chen, Y., Yock, T. I., Ebb, D. H., Choy, E., Raskin, K. A., Liebsch, N., et al. (2011) · Cancer · doi:10.1002/cncr.26037 · Cited by 191
Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk
Matsunobu, A., Imai, R., Kamada, T., Imaizumi, T., Tsuji, H., Tsujii, H., Shioyama, Y., Honda, H., Tatezaki, S., & for the Working Group for Bone and Soft Tissue Sarcomas (2012) · Cancer · doi:10.1002/cncr.27451 · Cited by 158
“Osteosarcoma is relatively radioresistant, and few reports have described effective local control using photon radiotherapy for osteosarcoma of the trunk.(6,7,15) Carbon ion radiotherapy (CIRT) has better dose distribution to the tumor compared with photon radiotherapy.”
BackgroundInfluentialFerrari, S., Bielack, S. S., Smeland, S., Longhi, A., Egerer, G., Sundby Hall, K., Donati, D., Kevric, M., Brosjö, O., Comandone, A., et al. (2018) · Tumori Journal · doi:10.5301/tj.5000696 · Cited by 123
Self-citation
Metadata
- Authors
- Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., Schwarz, R., von Hochstetter, A. R., Salzer-Kuntschik, M., Berdel, W. E., Jürgens, H., Exner, G. U., Reichardt, P., Mayer-Steinacker, R., Ewerbeck, V., Kotz, R., Winkelmann, W., & Bielack, S. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-01-15
- Volume
- 21
- Issue
- 2
- Pages
- 334-341
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121769039
- Cited by
- 342
- References
- 26
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.